Syntrix Pharmaceuticals https://validator.w3.org/feed/docs/rss2.html Blog Team Contact Us Internship Promo Bar: Basic Careers Partnering Research Immuno-Oncology Syntrix Publication in Bioorganic & Medicinal Chemistry Letters Syntrix Wins U.S. Patent 9,000,142: Photocleavable Sense-Antisense Complex Syntrix Wins U.S. Patent 8,993,541: Aminopyrimidine Carboxamides as CXCR2 Modulators Syntrix featured in the NIH Innovation Zone at 2014 Bio International Convention in San Diego, CA Syntrix wins U.S. patent 8,779,149: Aminopyridine and aminopyrimidine carboxamides as CXCR2 modulators Syntrix publication in Journal of Medicinal Chemistry Syntrix wins U.S. patent 8,969,365: Thiopyrimidinecarboxamides as CXCR1/2 modulators Syntrix wins U.S. patent 8,981,106: Pyrimidinecarboxamides as CXCR2 modulators Syntrix wins U.S. patent 8,748,623: Pyridinecarboxamides as CXCR2 modulators Syntrix publication in Bioorganic & Medicinal Chemistry Letters Syntrix Opens Investigational New Drug (IND) Application for SX-682, a Dual CXCR1 and CXCR2 Inhibitor Syntrix to Present at the 2016 Needham & Company 15th Annual Healthcare Conference Syntrix Wins U.S. Patent 9,480,694 – Thiopyrimidinecarboxamide for Use in Treating Pulmonary Disease Syntrix Receives $1.725M Grant to Conduct a Phase II Clinical Trial Investigating Omnitram for the treatment of Diabetic Neuropathic Pain Study Published in Nature Provides Path for New Immunotherapy to Prostate Cancer Using SX-682 – Results Underpin Clinical Trial of SX-682 With Anti-PD1 and Anti-CTLA4 Combination Syntrix Receives $2.965M Grant to Conduct a Phase Ib Clinical Trial Investigating Omnitram for the Treatment of Pain in Patients Resistant to Tramadol Syntrix Receives $2.3M Grant to Conduct a Phase 1/2 Clinical Trial Evaluating SX-682 Alone and with Pembrolizumab in Metastatic Melanoma Syntrix to Collaborate with NCI to Study SX-682 – Cooperative Research and Development Agreement (CRADA) Assesses SX-682 Alone and In Various Combinations Syntrix Wins U.S. Patent 10,046,002 – Method for Treating Cancer Using Chemokine Antagonists Desmetramadol featured today in new article by Research Outreach Syntrix Wins $3.4M NIH Grant to Conduct Phase 1/2 trial of SX-682 in Myelodysplastic Syndrome Syntrix Announces First Patient Cohort Dosed in Phase 2 Study of Desmetramadol in Diabetic Neuropathic Pain New Study Points to SX-682 as Strategy to Boost Immunotherapy Effectiveness in Advanced Colorectal Cancer Researchers Report SX-682 Could Enhance Multiple Forms of T Cell-Based Immunotherapies in Solid Tumors Syntrix Reports Positive Clinical Trials Showing Desmetramadol Has the Analgesic and Side Effect Profile of Tramadol Without Its Metabolic Liabilities Syntrix Announces Dosing of First Patient in Phase 1/2 Clinical Trial of SX-682 in Combination with KEYTRUDA® (pembrolizumab) in Metastatic Melanoma Syntrix Pharmaceuticals to Present Positive Desmetramadol Trial Results at the 2019 Pain Management SUMMIT Two New Reports Show SX-682 Blocks Key Immunosuppressive Tumor Cells to Enhance Checkpoint Inhibitors and NK-Based Cell Immunotherapies New Study Points to SX-682 as Novel Strategy to Broadly Increase the Effectiveness of Therapies Targeting the RAS/RAF/MEK/ERK Signaling Pathway in Non-Small Cell Lung Cancer First-in-Class Investigational SX-682 Demonstrates Single-Agent Efficacy in Patients with Hypomethylating Agent Failure Myelodysplastic Syndromes New study finds SX-682 leads to “unprecedented” response and cures in pancreatic cancer models World Health Organization’s INN Approves “Desmetramadol” as Generic Name for Omnitram Syntrix to present at 2025 Life Science Innovation Northwest (LSINW) ASCO 2024 selects SX-682 for oral podium presentation of positive first-in-class efficacy results in patients with metastatic melanoma Syntrix Wins U.S. Patent 9,707,248 – Use of Thiopyrimidinecarboxamide for Treating Cancer John A. Zebala, MD, PhD Syntrix Wins Three U.S. Patents for Omnitram – 9,717,700; 9,717,701; 9,808,432 Syntrix Doses First Subject with Omnitram to Confirm Pain Relief in Patients for Whom Tramadol is Ineffective Syntrix Joins National Cancer Institute (NCI) Formulary to Help Expedite Cancer Clinical Trials – Collaboration Will Support Vice President Biden’s Cancer Moonshot Program 404 Home